Esperion Q3 2023 Earnings Report
Key Takeaways
Esperion reported a 79% increase in total revenue to $34.0 million for Q3 2023, driven by a 45% increase in U.S. net product revenue and a 174% increase in collaboration revenue. The company also made progress toward label expansion, with FDA acceptance of cardiovascular risk reduction indication submissions in the U.S. The company reported a net loss of $41.3 million, and is preparing for new labels and sales organization changes to maximize the potential of NEXLETOL and NEXLIZET.
Total revenue increased by 79% year-over-year to $34.0 million.
U.S. net product revenue grew by 45% year-over-year to $20.3 million.
Collaboration revenue increased by 174% year-over-year to $13.7 million.
FDA accepted applications for expanded cardiovascular risk reduction indications with a PDUFA date of March 31.
Esperion
Esperion
Esperion Revenue by Segment
Forward Guidance
The company expects full year 2023 operating expenses to be approximately $225 million to $245 million, including $25 million in non-cash expenses related to stock compensation.
Revenue & Expenses
Visualization of income flow from segment revenue to net income